Inhaled Treprostinil for PAH: Open-label Extension

Inhaled Treprostinil in Subjects With Pulmonary Arterial Hypertension: An Open-Label, Phase III, International, Multi-Center Study

Status

Withdrawn

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01557660

Acronym

INTREPID - OL

Enrollment

Registered

2012-03-19

Start date

2012-06-30

Completion date

2018-12-31

Last updated

2012-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Arterial Hypertension

Brief summary

Open-label extension of RIN-PH-302.

Interventions

DRUGinhaled treprostinil

0.6mg/mL inhalation solution, up to 12 breaths four times a day

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Participation and completion of all required visits for study RIN-PH-302.

Design outcomes

Primary

Measure	Time frame
Long term safety of inhaled treprostinil	up to 5 years

Secondary

Measure	Time frame
Six-minute walk distance	up to 5 years

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026